** Orthocell OCC.AX jumps 7% to A$1.53; set for biggest intraday percentage gain since March 17

** Biotech firm receives U.S. FDA clearance to begin commercially distributing its flagship Remplir nerve repair product in the U.S.

** Stock sees busiest session since late February - 3.2 million shares traded, 2.1x the 30-day avg

** OCC gains 13.3% YTD

(Reporting by Jasmeen Ara Shaikh in Bengaluru)

((JasmeenAraIslam.Shaikh@thomsonreuters.com;))